Achaogen to Present at the Stifel 2017 Healthcare Conference


Press Release

<< Back
November 6, 2017 at 8:01 AM EST

Achaogen to Present at the Stifel 2017 Healthcare Conference

-- Company presentation scheduled for November 14, 2017 at 8:45 a.m. EST --

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will be presenting at the Stifel 2017 Healthcare Conference taking place November 14 to 15, 2017 at the Lotte New York Palace Hotel. Achaogen management will present at 8:45 a.m. Eastern Standard Time on Tuesday, November 14th, 2017.

A live audio webcast of the presentation will be available in the "Investors" section of Achaogen's website, www.achaogen.com. A replay of the presentation will be archived for 30 days following the conference for those unable to listen live.

About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. The Food and Drug Administration has granted plazomicin Breakthrough Therapy designation for the treatment of bloodstream infections caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options. The Company's second product candidate is C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination. Achaogen's plazomicin program has been funded, and its C-Scape program is funded, in part with Federal funds from the Biomedical Advanced Research and Development Authority. Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections and additional disease areas. All product candidates, including plazomicin, are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.

Source: Achaogen, Inc. (NASDAQ: AKAO)

Investor and Media Contact
David Arrington
Vice President, Investor Relations and Corporate Communications
650.440.5856
darrington@achaogen.com